BR0317095A - Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease - Google Patents
Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da proteaseInfo
- Publication number
- BR0317095A BR0317095A BR0317095-0A BR0317095A BR0317095A BR 0317095 A BR0317095 A BR 0317095A BR 0317095 A BR0317095 A BR 0317095A BR 0317095 A BR0317095 A BR 0317095A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- nnrti
- cytochrome
- reverse transcriptase
- protease inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"USO DE UMA COMBINAçãO CONTENDO UM INIBIDOR DA TRANSCRIPTASE REVERSA SEM SER DE NUCLEOSìDEO (NNRTI) COM UM INIBIDOR DO CITOCROMO P450, TAL COMO INIBIDORES DA PROTEASE". A presente invenção refere-se a um processo melhorado para a utilização de um NNRTI no tratamento da infecção pelo HIV-1, que compreende a administração a um ser humano, que necessita do tratamento para a infecção pelo HIV-1, de uma quantidade terapeuticamente eficaz do dito NNRTI ou de um sal farmaceuticamente aceitável do mesmo e uma quantidade de um inibidor dos citocromos P450 que é suficiente para elevar, melhorar ou estender as concentrações no plasma do dito NNRTI.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43369002P | 2002-12-16 | 2002-12-16 | |
| PCT/EP2003/014224 WO2004054586A1 (en) | 2002-12-16 | 2003-12-15 | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317095A true BR0317095A (pt) | 2005-10-25 |
Family
ID=32595224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317095-0A BR0317095A (pt) | 2002-12-16 | 2003-12-15 | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040152625A1 (pt) |
| EP (1) | EP1575595A1 (pt) |
| JP (1) | JP2006511538A (pt) |
| KR (1) | KR20050085681A (pt) |
| CN (1) | CN1726041A (pt) |
| AU (1) | AU2003296647A1 (pt) |
| BR (1) | BR0317095A (pt) |
| CA (1) | CA2510143A1 (pt) |
| EA (1) | EA200500894A1 (pt) |
| EC (1) | ECSP055854A (pt) |
| HR (1) | HRP20050557A2 (pt) |
| IL (1) | IL169099A0 (pt) |
| MX (1) | MXPA05005773A (pt) |
| NO (1) | NO20053455L (pt) |
| NZ (1) | NZ541187A (pt) |
| PL (1) | PL376900A1 (pt) |
| RS (1) | RS20050461A (pt) |
| UA (1) | UA81003C2 (pt) |
| WO (1) | WO2004054586A1 (pt) |
| ZA (1) | ZA200502947B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
| US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| ES2539527T3 (es) * | 2005-04-27 | 2015-07-01 | Taimed Biologics, Inc. | Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas |
| JP2009517412A (ja) | 2005-11-30 | 2009-04-30 | アンブリリア バイオファーマ インコーポレイテッド | アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法 |
| CN1907138B (zh) * | 2006-08-11 | 2011-01-12 | 华南师范大学 | 一种沙田柚子汁提取物及其提取方法和应用 |
| WO2008078200A2 (en) | 2006-09-21 | 2008-07-03 | Ambrilia Biopharma Inc. | Protease inhibitors |
| SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
| KR101471238B1 (ko) | 2009-04-25 | 2014-12-12 | 에프. 호프만-라 로슈 아게 | 약물동력학을 개선하는 방법 |
| MX2011012155A (es) | 2009-05-13 | 2012-02-28 | Enanta Pharm Inc | Compuestos macrociclicos como inhibidores del virus de hepatitis c. |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3955920A1 (en) | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696270A (en) * | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| IL111991A (en) * | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6410546B1 (en) * | 1997-04-07 | 2002-06-25 | Triangle Pharmaceuticals, Inc. | Use of MKC-442 in combination with other antiviral agents |
| WO2000025784A1 (en) * | 1998-11-04 | 2000-05-11 | Pharmacia & Upjohn Company | Method for improving the pharmacokinetics of tipranavir |
| US6391919B1 (en) * | 2000-01-12 | 2002-05-21 | Bristol-Myers Squibb Pharma Company | Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors |
| TWI270547B (en) * | 2000-06-16 | 2007-01-11 | Boehringer Ingelheim Ca Ltd | Non-nucleoside reverse transcriptase inhibitors |
| ATE331716T1 (de) * | 2002-09-19 | 2006-07-15 | Boehringer Ingelheim Ca Ltd | Nicht-nukleosidische inhibitoren der reverse transkriptase |
-
2003
- 2003-12-15 PL PL376900A patent/PL376900A1/pl not_active Application Discontinuation
- 2003-12-15 CN CNA2003801063012A patent/CN1726041A/zh active Pending
- 2003-12-15 WO PCT/EP2003/014224 patent/WO2004054586A1/en not_active Application Discontinuation
- 2003-12-15 EA EA200500894A patent/EA200500894A1/ru unknown
- 2003-12-15 US US10/736,301 patent/US20040152625A1/en not_active Abandoned
- 2003-12-15 EP EP03813119A patent/EP1575595A1/en not_active Withdrawn
- 2003-12-15 MX MXPA05005773A patent/MXPA05005773A/es not_active Application Discontinuation
- 2003-12-15 RS YUP-2005/0461A patent/RS20050461A/sr unknown
- 2003-12-15 AU AU2003296647A patent/AU2003296647A1/en not_active Abandoned
- 2003-12-15 NZ NZ541187A patent/NZ541187A/en unknown
- 2003-12-15 CA CA002510143A patent/CA2510143A1/en not_active Abandoned
- 2003-12-15 JP JP2004560402A patent/JP2006511538A/ja active Pending
- 2003-12-15 UA UAA200507057A patent/UA81003C2/uk unknown
- 2003-12-15 BR BR0317095-0A patent/BR0317095A/pt not_active IP Right Cessation
- 2003-12-15 KR KR1020057011003A patent/KR20050085681A/ko not_active Application Discontinuation
-
2005
- 2005-04-12 ZA ZA200502947A patent/ZA200502947B/en unknown
- 2005-06-09 IL IL169099A patent/IL169099A0/en unknown
- 2005-06-15 HR HR20050557A patent/HRP20050557A2/xx not_active Application Discontinuation
- 2005-06-15 EC EC2005005854A patent/ECSP055854A/es unknown
- 2005-07-15 NO NO20053455A patent/NO20053455L/no not_active Application Discontinuation
-
2007
- 2007-10-25 US US11/923,699 patent/US20080096832A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ541187A (en) | 2007-12-21 |
| CN1726041A (zh) | 2006-01-25 |
| IL169099A0 (en) | 2007-07-04 |
| PL376900A1 (pl) | 2006-01-09 |
| EA200500894A1 (ru) | 2006-02-24 |
| HRP20050557A2 (en) | 2006-05-31 |
| RS20050461A (en) | 2007-08-03 |
| NO20053455L (no) | 2005-08-10 |
| US20080096832A1 (en) | 2008-04-24 |
| UA81003C2 (en) | 2007-11-26 |
| JP2006511538A (ja) | 2006-04-06 |
| WO2004054586A1 (en) | 2004-07-01 |
| ECSP055854A (es) | 2006-01-16 |
| MXPA05005773A (es) | 2005-08-16 |
| AU2003296647A1 (en) | 2004-07-09 |
| CA2510143A1 (en) | 2004-07-01 |
| KR20050085681A (ko) | 2005-08-29 |
| US20040152625A1 (en) | 2004-08-05 |
| ZA200502947B (en) | 2008-01-30 |
| EP1575595A1 (en) | 2005-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
| MXPA04006553A (es) | Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih. | |
| MY147643A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
| BR0313747A (pt) | Inibidores de transcriptase reversa de não-nucleosìdeo | |
| BR0315166A (pt) | Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento | |
| DK1411932T3 (da) | Kombinationsterapi med substituerede oxazolidinoner | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| HUP0401998A2 (hu) | PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| BRPI0515896A (pt) | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus | |
| MY150903A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | |
| NO20034204L (no) | Farmasöytiske kombinasjoner til behandling av kreft | |
| MY148459A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression | |
| RU2009120990A (ru) | Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| BRPI0406796A (pt) | Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina | |
| MY144773A (en) | 6-(heterocycle-susbtituted benzyl) -4-oxoquinoline compound and use of the same as hiv integrase inhibitor | |
| HUP0400553A2 (hu) | Gyógyászati készítmények | |
| ATE376445T1 (de) | Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid- analoge | |
| EE200200087A (et) | Kompositsioon hepatotsellulaarse kartsinoomi raviks | |
| SE0004101D0 (sv) | New use | |
| EA199700150A1 (ru) | КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC | |
| HUP0402062A2 (hu) | Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények | |
| WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
| HUP0301915A2 (hu) | Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |